MIB Agents Now Accepting Letters of Intent for Annual OutSmarting Osteosarcoma Research Grants

Nonprofit Awards Grants to Projects Focused on Moving Research Forward for Rare Bone Cancer Patients

BARNARD, Vt., Sept. 24, 2025 /PRNewswire/ -- MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, families, medical professionals, researchers and industry partners, is accepting letters of intent (LOI) starting on Wednesday, September 24, for its annual OutSmarting Osteosarcoma research grant program. This program was established in 2017 and is awarded to projects focused on moving research forward for osteosarcoma patients. Osteosarcoma is an aggressive, malignant primary bone cancer affecting an estimated 1,000 people in the U.S. each year, about half of which are children and teens.

Over the past nine years, MIB Agents has awarded a total of $2.5M and supported 32 investigators to fund promising osteosarcoma research. In addition to a $100,000 Hero award, MIB Agents supports early career researchers with a $50,000 Young Investigator Research Hope award.

MIB Agents OutSmarting Osteosarcoma grants are supported by MIB Agents Family Funds, osteosarcoma patients and families who raise funds in honor of an OsteoWarrior, a patient currently battling osteosarcoma, or an OsteoAngel, a loved one who has passed.

"OutSmarting Osteosarcoma is more than a research grant. It's a partnership driven by families and scientists working side by side. Through Family Funds, osteosarcoma families raise and direct critical funding to support innovative projects and the career development of emerging investigators dedicated to this disease. By uniting patient voices with scientific expertise, we are accelerating discovery and working toward better treatments and brighter outcomes for those facing osteosarcoma," said Christina Ip-Toma, Director of Scientific Programs at MIB Agents.

OutSmarting Osteosarcoma Grants may also be supported in collaboration with other foundations that fundraise to support pediatric cancer research and are looking to fund studies that have been vetted by rigorous scientific peer review. 

Collaboration among the scientific and patient community is a key hallmark of MIB Agents that makes the OutSmarting Osteosarcoma grant process unique. Not only does the patient community partner to fund this grant every year, but they also have an active voice in the grant review process.

The OutSmarting Osteosarcoma review process involves rigorous scientific peer review by the MIB Agents Scientific Review Committee, during which participating Family Funds are invited to join as Stakeholder Reviewers, scoring applications on patient impact. The result is a collaborative and robust review process that uniquely incorporates patient and family perspectives.

To submit an LOI and for more information about eligibility and requirements, click https://www.mibagents.org/research/outsmarting-osteosarcoma. LOIs must be submitted on the Proposal Central online platform by October 24, 2025, at 11:59 pm ET. LOIs will be peer reviewed, and the highest-scoring proposals will be invited in early December to submit a full application by January 25, 2026. Award notification will be in early May 2026.

About MIB Agents

Founded in 2012 and established as an official 501(c)(3) nonprofit in 2016, MIB Agents is a leading pediatric osteosarcoma organization dedicated to making it better for our community of patients, families, medical professionals, researchers, and industry partners through programs, education, and research.

Media Contact:
MIB Agents
[email protected]
281.770.9084

SOURCE MIB Agents